Head and Neck Cancer Market

Head and Neck Cancer Market (Drug Class - EFGR Inhibitors, Mitotic Inhibitors, Anti-PD-1 Monoclonal Antibodies; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, E-commerce) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

Global Head and Neck Cancer Market – Snapshot

The global head and neck cancer market is driven by increase in the patient population, rise in health care infrastructure in developing economies, growth of the pharmaceutical industry, surge in research and development activity, increase in product approvals, and rise in government initiatives. An estimated 75% of head and neck cancers is caused due to consumption of alcohol and tobacco. However, high cost of treatment and high failure rate of late stage clinical trials are the major factors restraining the global market.

Head and Neck Cancer

The global head and neck cancer market has been segmented based on drug class, distribution channel, and region. In terms of drug class, the global market has been classified into EFGR inhibitors, mitotic inhibitors, anti-PD-1 monoclonal antibodies, and others. The anti-PD-1 monoclonal antibodies segment is projected to account for major share of the market by the end of the forecast period. Increase in research and development activity in the pharmaceutical industry, development of new products, and rise in mergers & acquisitions are expected to drive the segment during the forecast period. Based on distribution channel, the global head and neck cancer market has been classified into hospital pharmacies, retail pharmacies, and e-commerce. In terms of region, the global market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Based on drug class, the anti-PD-1 monoclonal antibodies segment is anticipated to dominate the global head and neck cancer market. Increase in awareness, rise in demand for efficient drugs for treatment, and new product approvals are expected to propel the segment during the forecast period. For instance, in November 2016, Bristol-Myers Squibb received the FDA approval for Opdivo (nivolumab) for intravenous treatment of individuals with metastatic squamous cell carcinoma of the head and neck (SCCHN)

In terms of distribution channel, the hospital pharmacies segment dominated the global head and neck cancer market. Increase in patient population and improvement in health care infrastructure are expected to drive the segment during the forecast period.

North America accounted for the largest share of the global market in 2017. Rise in prevalence of head and neck cancer (HNC), surge in health care expenditure, growth of the pharmaceutical industry, rise in mergers & acquisitions, and robust product pipeline are anticipated to drive the market in the region during the forecast period. Rise in demand for efficient drugs for treatment of HNCs in emerging economies such as China and India, growing pharmaceutical industry, and rapidly increasing patient population are anticipated to fuel the growth of the market in Asia Pacific during the forecast period. The head and neck cancer market in Latin America and Middle East & Africa is expected to be driven by rise in government initiatives to promote better health care facilities and increase in investment in health care sector during the forecast period. Growth of the health care industry, increase in the number of pharmaceutical companies, and rise in demand for therapeutics are expected to augment the market in these regions during the forecast period.

Major players operating in the global head and neck cancer market include Sanofi, Pfizer, Eli Lilly and Company, Merck KgaA, Bristol-Myers Squibb Company, Bayer AG, Galera, Fresenius Kabi, and Teva Pharmaceuticals. Increase in mergers & acquisitions, new product development, and strategic collaboration between major companies and governing authorities are expected to drive the global market during the forecast period. In October 2018, Sanofi received the FDA approval for TAXOTERE for the treatment of patients with head and neck cancer.

The global head and neck cancer market has been segmented as below:

Drug Class

  • EGFR Inhibitors
  • Mitotic Inhibitors
  • Anti-PD-1 Monoclonal Antibodies
  • Others

Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • E-commerce

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa


    1. Preface
       1.1. Market Definition and Scope
       1.2. Market Segmentation
       1.3. Key Research Objectives
       1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Head and Neck Cancer (HNC) Market

    4. Market Overview
       4.1. Introduction

            4.1.1. Drug Class Definition

            4.1.2. Industry Evolution / Developments
       4.2. Overview
       4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
       4.4. Global Head and Neck Cancer (HNC) Market Analysis and Forecasts, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)

    5. Market Outlook
       5.1. Key Mergers & Acquisitions
       5.2. Pipeline Analysis

    6. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Drug Class
       6.1. Introduction & Definition
       6.2. Key Findings / Developments
       6.3. Market Value Forecast, by Drug Class, 2016–2026
            6.3.1. EGFR Inhibitors
            6.3.2. Mitotic Inhibitors
            6.3.3. Anti-PD-1 Monoclonal Antibodies
            6.3.4. Others
       6.4. Market Attractiveness by Drug Class

    7. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Distribution Channel
       7.1. Introduction & Definition
       7.2. Key Findings / Developments
       7.3. Market Value Forecast, by Distribution Channel, 2016–2026
            7.3.1. Hospitals Pharmacies
            7.3.2. Retail Pharmacies
            7.3.3. E-commerce
       7.4. Market Attractiveness, by Distribution Channel

    8. Global Head and Neck Cancer (HNC) Market Analysis and Forecast, by Region
       8.1. Key Findings
       8.2. Market Value Forecast, by Region
            8.2.1. North America
            8.2.2. Europe
            8.2.3. Asia Pacific
            8.2.4. Latin America
            8.2.5. Middle East & Africa
       8.3. Market Attractiveness, by Country/Region

    9. North America Head and Neck Cancer (HNC) Market Analysis and Forecast
       9.1. Introduction
            9.1.1. Key Findings
       9.2. Market Value Forecast, by Drug Class, 2016–2026
            9.2.1. EGFR Inhibitors
            9.2.2. Mitotic Inhibitors
            9.2.3. Anti-PD-1 Monoclonal Antibodies
            9.2.4. Others
       9.3. Market Value Forecast, by Distribution Channel, 2016–2026
            9.3.1. Hospitals Pharmacies
            9.3.2. Retail Pharmacies
            9.3.3. E-commerce
       9.4. Market Value Forecast, by Country, 2016-2026
            9.4.1. U.S.
            9.4.2. Canada
       9.5. Market Attractiveness Analysis
            9.5.1. By Drug Class
            9.5.2. By Distribution Channel
            9.5.3. By Country

    10. Europe Head and Neck Cancer (HNC) Market Analysis and Forecast
       10.1. Introduction
            10.1.1. Key Findings
       10.2. Market Value Forecast, by Drug Class, 2016–2026
            10.2.1. EGFR Inhibitors
            10.2.2. Mitotic Inhibitors
            10.2.3. Anti-PD-1 Monoclonal Antibodies
            10.2.4. Others
       10.3. Market Value Forecast, by Distribution Channel, 2016–2026
            10.3.1. Hospitals Pharmacies
            10.3.2. Retail Pharmacies
            10.3.3. E-commerce
       10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            10.4.1. Germany
            10.4.2. U.K.
            10.4.3. France
            10.4.4. Italy
            10.4.5. Spain
            10.4.6. Rest of Europe
       10.5. Market Attractiveness Analysis
            10.5.1. By Drug Class
            10.5.2. By Distribution Channel
            10.5.3. By Country/Sub-region

    11. Asia Pacific Head and Neck Cancer (HNC) Market Analysis and Forecast
       11.1. Introduction
            11.1.1. Key Findings
       11.2. Market Value Forecast, by Drug Class, 2016–2026
            11.2.1. EGFR Inhibitors
            11.2.2. Mitotic Inhibitors
            11.2.3. Anti-PD-1 Monoclonal Antibodies
            11.2.4. Others
       11.3. Market Value Forecast, by Distribution Channel, 2016–2026
            11.3.1. Hospitals Pharmacies
            11.3.2. Retail Pharmacies
            11.3.3. E-commerce
       11.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            11.4.1. China
            11.4.2. India
            11.4.3. Japan
            11.4.4. Australia & New Zealand
            11.4.5. Rest of APAC
       11.5. Market Attractiveness Analysis
            11.5.1. By Drug Class
            11.5.2. By Distribution Channel
            11.5.3. By Country/Sub-region

    12. Latin America Head and Neck Cancer (HNC) Market Analysis and Forecast
       12.1. Introduction
            12.1.1. Key Findings
       12.2. Market Value Forecast, by Drug Class, 2016–2026
            12.2.1. EGFR Inhibitors
            12.2.2. Mitotic Inhibitors
            12.2.3. Anti-PD-1 Monoclonal Antibodies
            12.2.4. Others
       12.3. Market Value Forecast, by Distribution Channel, 2016–2026
            12.3.1. Hospitals Pharmacies
            12.3.2. Retail Pharmacies
            12.3.3. E-commerce
       12.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            12.4.1. Brazil
            12.4.2. Mexico
            12.4.3. Rest of LATAM
       12.5. Market Attractiveness Analysis
            12.5.1. By Drug Class
            12.5.2. By Distribution Channel
            12.5.3. By Country/Sub-region

    13. Middle East & Africa Head and Neck Cancer (HNC) Market Analysis and Forecast
       13.1. Introduction
            13.1.1. Key Findings
       13.2. Market Value Forecast, by Drug Class, 2016–2026
            13.2.1. EGFR Inhibitors
            13.2.2. Mitotic Inhibitors
            13.2.3. Anti-PD-1 Monoclonal Antibodies
            13.2.4. Others
       13.3. Market Value Forecast, by Distribution Channel, 2016–2026
            13.3.1. Hospitals Pharmacies
            13.3.2. Retail Pharmacies
            13.3.3. E-commerce
       13.4. Market Value Forecast, by Country/Sub-region, 2016–2026
            13.4.1. GCC Countries
            13.4.2. South Africa
            13.4.3. Rest of MEA
       13.5. Market Attractiveness Analysis
            13.5.1. By Drug Class
            13.5.2. By Distribution Channel
            13.5.3. By Country/Sub-region

    14. Competition Landscape
       14.1. Market Player - Competition Matrix (By Tier and Size of companies)
       14.2. Market Share Analysis, by Company (2017)
       14.3. Company Profiles
            14.3.1. Sanofi
                   14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.1.2. Financial Overview
                   14.3.1.3. Product Portfolio
                   14.3.1.4. SWOT Analysis
                   14.3.1.5. Strategic Overview
            14.3.2. Pfizer
                   14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.2.2. Financial Overview
                   14.3.2.3. Product Portfolio
                   14.3.2.4. SWOT Analysis
                   14.3.2.5. Strategic Overview
            14.3.3. Eli Lilly and Company
                   14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.3.2. Financial Overview
                   14.3.3.3. Product Portfolio
                   14.3.3.4. SWOT Analysis
                   14.3.3.5. Strategic Overview
            14.3.4. AstraZeneca
                   14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.4.2. Financial Overview
                   14.3.4.3. Product Portfolio
                   14.3.4.4. SWOT Analysis
                   14.3.4.5. Strategic Overview
            14.3.5. Teva Pharmaceuticals
                   14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.5.2. Financial Overview
                   14.3.5.3. Product Portfolio
                   14.3.5.4. SWOT Analysis
                   14.3.5.5. Strategic Overview
            14.3.6. F. Hoffmann-La Roche Ltd.
                   14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.6.2. Financial Overview
                   14.3.6.3. Product Portfolio
                   14.3.6.4. SWOT Analysis
                   14.3.6.5. Strategic Overview
            14.3.7. Fresenius Kabi
                   14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.7.2. Financial Overview
                   14.3.7.3. Product Portfolio
                   14.3.7.4. SWOT Analysis
                   14.3.7.5. Strategic Overview
            14.3.8. Merck
                   14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.8.2. Financial Overview
                   14.3.8.3. Product Portfolio
                   14.3.8.4. SWOT Analysis
                   14.3.8.5. Strategic Overview
            14.3.9. Bayer AG
                   14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.9.2. Financial Overview
                   14.3.9.3. Product Portfolio
                   14.3.9.4. SWOT Analysis
                   14.3.9.5. Strategic Overview
            14.3.10. Bristol-Myers Squibb Company
                   14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.10.2. Financial Overview
                   14.3.10.3. Product Portfolio
                   14.3.10.4. SWOT Analysis
                   14.3.10.5. Strategic Overview
            14.3.11. Galera
                   14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
                   14.3.11.2. Financial Overview
                   14.3.11.3. Product Portfolio
                   14.3.11.4. SWOT Analysis
                   14.3.11.5. Strategic Overview

     

    List of Tables

    Table 01: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 02: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 03: Global Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Region, 2016–2026
    Table 04: North America Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country, 2016–2026
    Table 05: North America Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 06: North America Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel,
    Table 07: Europe Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 08: Europe Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 09: Europe Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 10: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 11: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 12: Asia Pacific Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 13: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Country/Sub-region,
    Table 14: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 15: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 16: Middle East & Africa Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 17: Middle East & Africa Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 18: Middle East & Africa Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026

    List of Figures

    Figure 01: Global Head and Neck Cancer (HNC) Market Size Value (US$ Mn) Forecast, 2016–2026
    Figure 02: Global Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class (2017)
    Figure 03: Global Head and Neck Cancer (HNC) Market Value Share (%), by Distribution Channel (2017)
    Figure 04: Global Head and Neck Cancer (HNC) Market Value Share (%), by Region (2017) 
     Figure 05: Global Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
    Figure 06: Global Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
    Figure 07: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by EGFR Inhibitors, 2016–2026
    Figure 08: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Mitotic Inhibitors, 2016–2026
    Figure 09: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Anti-PD-1 Monoclonal Antibodies, 2016–2026
    Figure 10: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others,
    Figure 11: Global Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 12: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by
    Figure 13: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
    Figure 14: Global Head and Neck Cancer (HNC) Market Revenue (US$ Mn) and Y-o-Y Growth (%), by E-commerce, 2016–2026
    Figure 15: Global Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 16: Global Head and Neck Cancer (HNC) Market Value Share Analysis, by Region, 2018 and 2026
    Figure 17: Global Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Region, 2018–2026
    Figure 18: North America Head and Neck Cancer (HNC) Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 19: North America Head and Neck Cancer (HNC) Market Value Share Analysis, by Country, 2018 and 2026
    Figure 20: North America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country, 2018–2026
     Figure 21: North America Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
    Figure 22: North America Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
    Figure 23: North America Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 24: North America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
    Figure 25: Europe Head and Neck Cancer (HNC) Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 26: Europe Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 27: Europe Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
     Figure 28: Europe Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
    Figure 29: Europe Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
    Figure 30: Europe Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 31: Europe Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
    Figure 32: Asia Pacific Head and Neck Cancer (HNC) Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 33: Asia Pacific Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 34: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
     Figure 35: Asia Pacific Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
    Figure 36: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
    Figure 37: Asia Pacific Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 38: Asia Pacific Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
    Figure 39: Latin America Head and Neck Cancer (HNC) Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2016–2026
    Figure 40: Latin America Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 41: Latin America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
     Figure 42: Latin America Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
    Figure 43: Latin America Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
    Figure 44: Latin America Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 45: Latin America Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018-2026
    Figure 46: Middle East & Africa Head and Neck Cancer (HNC) Market Size (US$ Mn) Forecast, 2016–2026
    Figure 47: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 48: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
     Figure 49: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share (%), by Drug Class, 2018 and 2026
    Figure 50: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness, by Drug Class, 2018–2026
    Figure 51: Middle East & Africa Head and Neck Cancer (HNC) Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 52: Middle East & Africa Head and Neck Cancer (HNC) Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 53: Global Head and Neck Cancer (HNC) Market Share, by Company, 2017
    Figure 54: AstraZeneca Oncology Business Revenue (US$ Bn) & Y-o-Y Growth (%), 2014 –2017
    Figure 55: AstraZeneca R&D in Oncology Segment Revenue (US$ Bn) & Y-o-Y Growth (%), 2014 –2017
    Figure 56: AstraZeneca's Oncology Business Segment Revenue (% Share), by Region, 2017
    Figure 57: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 58: Eli Lilly and Company Breakdown of Net Sales, by Region, 2017
    Figure 59: Eli Lilly and Company Breakdown of Net Sales, by Business Segment, 2017
    Figure 60: Eli Lilly and Company Research and Development Cost, 2016 and 2017 (US$ Mn)
    Figure 61: Pfizer, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
    Figure 62: Pfizer, Inc.’s Oncology Business Segment Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2017
    Figure 64: Pfizer, Inc.’s Revenue (% Share), by Business Segment, 2017
    Figure 64: Pfizer, Inc.’s Revenue (% Share), by Business Segment, 2017
    Figure 66: Novartis AG Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 67: Novartis AG Oncology Business Segment Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
    Figure 68: Novartis AG’s Net Sales (% Share), by Business Segment, 2017
    Figure 69: Novartis AG’s Net Sales (% Share), by Region, 2017
    Figure 70: Bristol-Myers Squibb Company Revenue (US$ Bn), 2014-2017
    Figure 71: Bristol-Myers Squibb Company R&D Expenditure (US$ Bn), 2015- 2017
    Figure 72: Bristol-Myers Squibb Company Revenue, by Geography, 2017
    Figure 73: Bayer AG Pharmaceutical Business Segment Revenue (US$ Bn), 2015-2017
    Figure 74: Bayer AG Pharmaceutical Business Segment R&D Expenditure (US$ Bn), 2015-2017
    Figure 75: Bayer AG Pharmaceutical Business Segment Revenue, by Geography (2017)
    Figure 76: F. Hoffmann-La Roche Ltd. Oncology Segment Revenue (US$ Bn), 2015–2017
    Figure 77: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment R&D Expenditure (US$ Bn), 2015–2017
    Figure 78: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue, by Specialty (2017)
    Figure 79: F. Hoffmann-La Roche Ltd. Pharmaceutical Segment Revenue, by Region (2017)
    Figure 80: Sanofi Revenue (US$ Bn), 2014-2017
    Figure 81: Sanofi Regional Sales Breakdown (%), 2017
    Figure 82: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 83: Teva Pharmaceutical Industries Ltd. Segmental Revenue (US$ Bn), 2017
    Figure 84: Fresenius SE & Co. KGaA Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
    Figure 85: Fresenius SE & Co. KGaA Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 86: Merck KGaA Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2017
    Figure 87: Merck KGaA Revenue, by Geography (%), 2017
    Figure 88: Merck KGaA Revenue, by Business Segment (%), 2014–2017

Copyright © Transparency Market Research, Inc. All Rights reserved